Glioblastoma multiforme (GBM) is the most common primary malignant tumor of the adult central nervous system (CNS). Although oncolytic virotherapy represents an attractive therapy for this cancer, one of the major limitations of this approach entails immune response to viral vectors. This proposal seeks to evaluate the role of regulatory T cells in anti-viral and anti-tumoral immunity in the setting of oncolytic virotherapy of brain tumors in order to advance this strategy to the clinical setting.
|Effective start/end date||4/1/16 → 4/30/17|
- National Cancer Institute (7R01CA122930-09)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.